Compare RS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RS | GH |
|---|---|---|
| Founded | 1939 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 13.3B |
| IPO Year | 1996 | 2018 |
| Metric | RS | GH |
|---|---|---|
| Price | $298.56 | $87.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 20 |
| Target Price | ★ $328.50 | $117.80 |
| AVG Volume (30 Days) | 314.7K | ★ 1.5M |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 13.98 | N/A |
| Revenue | ★ $14,805,900,000.00 | $982,021,000.00 |
| Revenue This Year | $9.32 | $33.40 |
| Revenue Next Year | $1.11 | $28.32 |
| P/E Ratio | $21.45 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $250.07 | $36.36 |
| 52 Week High | $365.59 | $120.74 |
| Indicator | RS | GH |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 43.13 |
| Support Level | $287.99 | $82.26 |
| Resistance Level | $335.13 | $90.28 |
| Average True Range (ATR) | 7.36 | 3.61 |
| MACD | 0.52 | 0.45 |
| Stochastic Oscillator | 52.60 | 59.11 |
Reliance Inc operates a network of companies providing diversified metal solutions and is the metals service center company. It distributes a full line of over 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium and other specialty steel products. The company services more than 125,000 customers in a variety of industries, including consumer products, general manufacturing, non-residential construction, transportation, aerospace, energy, electronics and semiconductor fabrication, industrial machinery and heavy industry. It also services the auto industry, through its toll processing operations where it processes customer-owned metal for a fee.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.